Evaxion Biotech (EVAX) Life Sciences Investor Forum 2024 summary

AI platform and business model

• AI-first approach enables rapid and effective vaccine target discovery for cancer and infectious diseases, reducing target identification from years to 24 hours.

• Proprietary data and continuous model validation enhance predictive accuracy and allow discovery of novel targets not accessible by conventional methods.

• The platform supports both personalized cancer vaccines and infectious disease vaccines, with speed and accuracy as key differentiators.

• Recent upgrade to the EDEN model now enables prediction of bacterial toxins, expanding its utility in infectious disease research.

• Broad interest from partners in target discovery collaborations and AI-derived vaccine candidates, with a focus on monetizing assets rather than sharing raw data.

Clinical and preclinical pipeline updates

• Lead candidate EVX-01, a personalized neoantigen vaccine for metastatic melanoma, showed a 69% overall response rate in phase II, improving on earlier results.

• 15 out of 16 patients in the phase II trial experienced tumor size reduction, indicating strong efficacy and commercial potential.

• Preclinical proof of concept for EVX-B2, a gonorrhea vaccine, demonstrated effectiveness in both peptide and mRNA constructs, confirming the platform's delivery modality agnosticism.

• Collaboration with Afrigen Biologics supports the development of mRNA-based vaccines, broadening partnership opportunities.

Regulatory and industry positioning

• Ongoing engagement with global regulatory authorities, including FDA Fast Track designation for EVX-01, reflects acceptance of AI-derived vaccine candidates.

• Regulatory bodies are interested in integrating AI into frameworks, though no current acceleration of approval timelines is noted.

• Longstanding AI expertise and proprietary data position the company as a pioneer in the TechBio sector.